ArticleNature2025
Selective inhibition of stromal mechanosensing suppresses cardiac fibrosis.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Nuclear mechanotransduction: tools for mechanical perturbation and chromatin characterization.Nucleus (Austin, Tex.) · 2026Review
- Reconstructing AF-associated atrial fibrosis: Patient-specific iPSC models, fit-for-purpose atrial microphysiological systems, and nanomedicine.Materials today. Bio · 2026Review
- New approach methodologies: drug screening platform to identify antifibrotic compounds.Nature protocols · 2026Review
- Mechanical-medical convergence in heart failure: Artificial intelligence, finite-element modeling, and 3D printing for diagnosis and prognosis.Bioengineering & translational medicine · 2026Review
- The Role of Cardiac Fibrosis and Fibroblast Activation in Amyloid Light Chain (AL) Amyloidosis.JACC. Basic to translational science · 2026Article
- Therapeutic modulation of the vitreoretinal fibrosis microenvironment in female mice using engineered macrophage-derived extracellular vesicles.Nature communications · 2026Article
- Cardiac fibroblast diversity in HFpEF: states, niches, interorgan drivers and targets.Nature reviews. Cardiology · 2026Review
- A practical toolbox for modelling fibrosis in vitro.Nature biomedical engineering · 2026Review
- FUNDC1-mediated mitochondrial quality control protects against immune checkpoint inhibitor-associated cardiac injury.Immunologic research · 2026Article
- Cardiac immunity and heart repair: Mechanism, challenge, and future direction.Chinese medical journal · 2026Review
- Article
- Matrix stiffness induced CREB3L1 activation contributed to skin fibrosis through calcium influx triggered endoplasmic reticulum stress.Cellular and molecular life sciences : CMLS · 2026Article
- Shared mechanisms of organ fibrosis.JCI insight · 2026Review
- Single Cell Mechanics in Disease Progression.Small science · 2026Review
- From force to fate: Implications of mechanomemory in lung disease.Respiratory research · 2026Review
- Intercellular chemerin-cmklr1 couples epicardial mechanosensing to fibroblasts in pressure overload.Nature communications · 2026Article
- Cardiac mechanotransduction from development to disease.APL bioengineering · 2026Review
- ECM-Stiffness Mediated Persistent Fibroblast Activation Requires Integrin and Formin Dependent Chromatin Remodeling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cardiac fibroblasts in myocardial injury and heart failure.European heart journal · 2026Review
- An orally bioavailable pan-αv/α5β1 integrin antagonist prevents aggressive prostate cancer progression via suppressing both oncogenic signals and CD47-mediated immune escape.Molecular cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Sangkyun Cho *Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA. sangcho@stanford.edu.ORCID 0000-0003-2961-2847
Siyeon Rhee *Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-7642-4016
Christopher M MadlDepartment of Microbiology and Immunology, Stanford University, Stanford, CA, USA.ORCID 0000-0003-3221-5041
Arianne CaudalStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-9836-9436
Dilip ThomasStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Hyeonyu KimStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Ana KojicStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Hye Sook ShinStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Abhay MahajanStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0009-0003-9731-5497
James W JahngStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Xi WangCOPPER Laboratory, Ohio State University, Columbus, OH, USA.
Phung N ThaiDepartment of Internal Medicine, University of California, Davis, Davis, CA, USA.ORCID 0000-0001-7344-150X
David T PaikStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-7830-312X
Mingqiang WangStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
McKay MullenStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Natalie M BakerStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Jeremy LeitzGreenstone Biosciences, Palo Alto, CA, USA.
Souhrid MukherjeeGreenstone Biosciences, Palo Alto, CA, USA.ORCID 0000-0002-8355-3000
Virginia D WinnStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-1136-2907
Y Joseph WooStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-2506-492X
Helen M BlauStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-6503-5480
Joseph C WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA. joewu@stanford.edu.ORCID 0000-0002-6068-8041
Funding
Elucidating Mechanism of Cardiac Fibrosis with Cell Village of Pooled Human iPSCsR01HL130020 · NHLBI · STANFORD UNIVERSITY · PI Ronglih Liao, MARK MERCOLA · 2016 to 2026
$7.3MHuman Induced Pluripotent Stem Cells for Cardiovascular Disease ModelingR01HL113006 · NHLBI · STANFORD UNIVERSITY · PI WU, JOSEPH C. · 2012 to 2025
$6.8MHuman iPSCs for Elucidating Intercellular Crosstalk Signaling in Dilated CardiomyopathyR01HL141371 · NHLBI · STANFORD UNIVERSITY · PI WONG, WING H., WU, JOSEPH C. · 2018 to 2025
$6.2MModeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCsR01HL141851 · NHLBI · STANFORD UNIVERSITY · PI WONG, WING H., WU, JOSEPH C. · 2018 to 2025
$5.7MSingle Cell Sequencing of Human iPSC-CM Subtype Identity and FunctionR01HL145676 · NHLBI · STANFORD UNIVERSITY · PI MARK MERCOLA, Joseph C. Wu · 2019 to 2026
$5.1MHuman iPSC Model to Elucidate Metabolic Interplay in Diabetic CardimyopathyR01HL146690 · NHLBI · STANFORD UNIVERSITY · PI LIAO, RONGLIH, MERCOLA, MARK · 2019 to 2025
$5.1MElucidating Anthracycline-Induced Cell Type-Specific Cardiovascular Toxicity with CRISPRi/a ScreensR01HL150693 · NHLBI · STANFORD UNIVERSITY · PI Ronglih Liao, Joseph C. Wu · 2021 to 2026
$4.1MElucidating ECM Signaling in Cardiac Organoids with Machine Learning and Single-cell MultiomicsR01HL163680 · NHLBI · STANFORD UNIVERSITY · PI RAJADAS, JAYAKUMAR, WONG, WING H. · 2022 to 2025
$2.5MElucidating the Role of Microenvironment Mechanics in Regulating Cardiac Myofibroblast PlasticityR00HL166695 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Sangkyun Cho · 2025 to 2026
$497kElucidating the Role of Microenvironment Mechanics in Regulating Cardiac Myofibroblast PlasticityK99HL166695 · NHLBI · STANFORD UNIVERSITY · PI CHO, SANGKYUN · 2023 to 2024
$261kUnraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac OrganoidsK99HL163443 · NHLBI · STANFORD UNIVERSITY · PI THOMAS, DILIP · 2023 to 2024
$249kHuman iPSCs for Elucidating Stress-mediated Paracrine Signaling in Dilated CardiomyopathyF32HL152483 · NHLBI · STANFORD UNIVERSITY · PI CHO, SANGKYUN · 2020 to 2021
$127kNHLBI NIH HHS F32 HL152483NHLBI NIH HHS F32 HL173968NHLBI NIH HHS K99 HL163443NHLBI NIH HHS K99 HL166695NHLBI NIH HHS R00 HL166695NHLBI NIH HHS R01 HL113006NHLBI NIH HHS R01 HL130020NHLBI NIH HHS R01 HL141371NHLBI NIH HHS R01 HL141851NHLBI NIH HHS R01 HL145676NHLBI NIH HHS R01 HL146690NHLBI NIH HHS R01 HL150693NHLBI NIH HHS R01 HL163680
Abstract
Matrix-derived biophysical cues are known to regulate the activation of fibroblasts and their subsequent transdifferentiation into myofibroblasts
Indexed as
Mechanotransduction, CellularMyocardiumStromal CellsAnimalsBenzodioxolesDisease Models, AnimalExtracellular MatrixFemaleFibroblastsFibrosisHeart FailureHumansMaleMiceMyofibroblastsSingle-Cell AnalysisBenzodioxolessrc-Family KinasesTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.